Evidence map›Paper›PMID 28731051›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2017

Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center.

Alexander H R Varey, Chris Goumas, Angela M Hong, Graham J Mann, Gerald B Fogarty, Jonathan R Stretch, Robyn P M Saw, Andrew J Spillane, Kerwin F Shannon, Kenneth J Lee and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Radiotherapy for Melanoma: More than DNA Damage.Dermatology research and practice · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Alexander H R VareyMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
Chris GoumasMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
Angela M HongMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
Graham J MannMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
Gerald B FogartyMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
Jonathan R StretchMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
Robyn P M SawMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
Andrew J SpillaneMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
Kerwin F ShannonMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.ORCID 0000-0001-8538-3132
Kenneth J LeeMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
Michael J QuinnMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
John F ThompsonMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
Richard A ScolyerMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
The University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurotropic cutaneous melanoma is a rare melanoma subtype that invades nerves and is often associated with desmoplastic melanoma. Limited data suggest that it has a greater propensity to recur locally, but it is unknown whether its behavior differs from that of other melanoma subtypes, including desmoplastic melanoma. We investigated clinicopathological predictors of outcome in a cohort of 671 patients with neurotropic melanoma to develop evidence-based management recommendations. Patients with primary neurotropic melanoma diagnosed from 1985 to 2013 were identified from the Melanoma Institute Australia database, along with a control cohort of 718 non-neurotropic melanoma patients. Features predictive of sentinel lymph node status, recurrence, melanoma-specific survival and response to adjuvant radiotherapy were sought. Neither local recurrence (hazard ratio: 1.28 (0.73-2.25) P=0.39) nor melanoma-specific survival (hazard ratio: 0.79 (0.55-1.15) P=0.22) were significantly affected by the presence of neurotropism on multivariate analysis. However, there was a markedly reduced likelihood of sentinel node positivity (hazard ratio: 0.61 (0.41-0.89) P=0.01) in neurotropic melanoma patients. Surgical margins ≥8mm halved the recurrence risk compared with <2 mm margins (hazard ratio: 0.46 (0.31-0.68) P<0.001). Additionally, in neurotropic melanoma patients with <8 mm margins, adjuvant radiotherapy halved the recurrence risk (hazard ratio: 0.48 (0.27-0.87) P=0.02). This, the largest study of neurotropic melanoma reported to date, has demonstrated that the presence of neurotropism does not alter the risk of melanoma recurrence or survival but does reduce the likelihood of sentinel node positivity. For successful treatment of neurotropic melanoma, adequate excision margins are of paramount importance. However, when adequate margins cannot be achieved, adjuvant radiotherapy reduces the risk of recurrence.

Indexed as

AdultAgedCutaneous Malignant MelanomaDisease-Free SurvivalFemaleHumansLymphatic MetastasisMaleMelanomaMiddle AgedNeoplasm Recurrence, LocalProportional Hazards ModelsSkin NeoplasmsTertiary Care Centers

Identifiers

PMID28731051
OpenAlexW2738411509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.